D.A. Davidson & CO. Acquires New Position in Genomic Health, Inc. (GHDX)

D.A. Davidson & CO. acquired a new position in Genomic Health, Inc. (NASDAQ:GHDX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 3,330 shares of the medical research company’s stock, valued at approximately $234,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GHDX. First Quadrant L P CA lifted its position in shares of Genomic Health by 2,575.5% in the third quarter. First Quadrant L P CA now owns 21,083 shares of the medical research company’s stock worth $1,480,000 after buying an additional 20,295 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Genomic Health by 30.7% in the second quarter. Bank of New York Mellon Corp now owns 122,246 shares of the medical research company’s stock worth $6,161,000 after buying an additional 28,710 shares in the last quarter. Northern Trust Corp lifted its position in shares of Genomic Health by 4.7% in the second quarter. Northern Trust Corp now owns 282,021 shares of the medical research company’s stock worth $14,214,000 after buying an additional 12,597 shares in the last quarter. Millennium Management LLC lifted its position in shares of Genomic Health by 114.0% in the second quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after buying an additional 770,413 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Genomic Health in the second quarter worth about $213,000. 89.21% of the stock is owned by hedge funds and other institutional investors.

In other Genomic Health news, Director Bros. Advisors Lp Baker sold 195,134 shares of the company’s stock in a transaction that occurred on Friday, December 7th. The stock was sold at an average price of $75.82, for a total transaction of $14,795,059.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Frederic Pla sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $65.43, for a total value of $98,145.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,635,985 shares of company stock worth $126,469,701. Company insiders own 45.80% of the company’s stock.

Shares of GHDX stock opened at $72.90 on Friday. Genomic Health, Inc. has a 1 year low of $26.54 and a 1 year high of $92.18. The company has a market cap of $2.67 billion, a price-to-earnings ratio of 7,290.00 and a beta of 0.40.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.28. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The business had revenue of $101.30 million for the quarter, compared to the consensus estimate of $94.27 million. During the same period in the prior year, the business posted ($0.06) earnings per share. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts predict that Genomic Health, Inc. will post 1.06 EPS for the current year.

A number of equities research analysts recently commented on the company. Zacks Investment Research downgraded Genomic Health from a “buy” rating to a “hold” rating in a research report on Thursday, August 30th. BidaskClub downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Canaccord Genuity reiterated a “buy” rating and issued a $82.00 target price (up from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. Finally, Raymond James assumed coverage on Genomic Health in a research report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $48.33.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/08/d-a-davidson-co-acquires-new-position-in-genomic-health-inc-ghdx.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: Using the New Google Finance Tool

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply